Literature DB >> 12271111

Moderating effects of coping on the relationship between stress and the development of new brain lesions in multiple sclerosis.

David C Mohr1, Donald E Goodkin, Sarah Nelson, Darcy Cox, Michael Weiner.   

Abstract

OBJECTIVE: Many patients with multiple sclerosis (MS) report that stress can trigger disease exacerbations. Considerable research has supported a relationship between stress and both clinical exacerbation and the development of new brain lesions. However, these relationships are not always consistent either within patients or across patients, suggesting the presence of moderators. This study examined the hypothesis that coping moderates the subsequent relationship between stress and the development of new brain lesions in MS.
METHODS: Thirty-six patients (mean age = 44.4; 22 women, 14 men) with relapsing forms of MS were assessed once every 4 weeks for 28-100 weeks. New brain lesions were identified using monthly Gd+ MRI. Stress was measured within 24 hours before MRI using a modified version of the Social Readjustment Rating Scale that assessed Conflict and Disruption in Routine. Coping was measured at baseline using the Coping with Health Injuries and Problems questionnaire, which produces four scales: distraction, instrumental, palliative, and emotional preoccupation. Data were analyzed using mixed effects logistic regression to account for within-subject correlations. Analyses were lagged such that stress assessments predicted new Gd+ MRI brain lesions 8 weeks later.
RESULTS: As reported previously, stress was significantly related to the development of new Gd+ brain lesions 8 weeks later (OR = 1.62, p =.009). Greater use of distraction was found to be a significant moderator of the relationship between stress and new Gd+ lesions (OR = 0.69, p =.037) such that greater use of distraction was associated with a decreased relationship between stress and new Gd+ lesions. Increased instrumental coping was marginally associated with a decreased relationship between stress and new Gd+ lesions (OR = 0.77, p =.081), while increased emotional preoccupation was marginally associated with an increased relationship between stress and new Gd+ lesions (OR = 1.46, p =.088). There was no significant moderating effect for palliative coping (p =.27) and no significant main effects for any coping variables and the subsequent development of new Gd+ brain lesions (p values >.21).
CONCLUSIONS: These findings provide modest support for the hypothesis that coping can moderate the relationship between stress and the MS disease activity. Several limitations in this study are discussed. While these findings suggest areas of potentially fruitful research, readers are cautioned that these are preliminary results; inferences regarding the clinical importance of these findings are premature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271111      PMCID: PMC1893006          DOI: 10.1097/01.psy.0000024238.11538.ec

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  47 in total

1.  Revised estimate of the prevalence of multiple sclerosis in the United States.

Authors:  D W Anderson; J H Ellenberg; C M Leventhal; S C Reingold; M Rodriguez; D H Silberberg
Journal:  Ann Neurol       Date:  1992-03       Impact factor: 10.422

2.  Severely threatening events and marked life difficulties preceding onset or exacerbation of multiple sclerosis.

Authors:  I Grant; G W Brown; T Harris; W I McDonald; T Patterson; M R Trimble
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

4.  The psychosocial impact of multiple sclerosis: exploring the patient's perspective.

Authors:  D C Mohr; L P Dick; D Russo; J Pinn; A C Boudewyn; W Likosky; D E Goodkin
Journal:  Health Psychol       Date:  1999-07       Impact factor: 4.267

5.  Emotional stress and coping in multiple sclerosis (MS) exacerbations.

Authors:  S Warren; K G Warren; R Cockerill
Journal:  J Psychosom Res       Date:  1991       Impact factor: 3.006

6.  Psychological stress as risk factor for exacerbations in multiple sclerosis.

Authors:  P Nisipeanu; A D Korczyn
Journal:  Neurology       Date:  1993-07       Impact factor: 9.910

7.  Validation of a Telephone Cognitive Assessment Battery.

Authors:  S M Debanne; M B Patterson; R Dick; T M Riedel; A Schnell; D Y Rowland
Journal:  J Am Geriatr Soc       Date:  1997-11       Impact factor: 5.562

8.  Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.

Authors:  F Barkhof; M W Tas; S T Frequin; P Scheltens; O R Hommes; J J Nauta; J Valk
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

9.  Emotional stress and the development of multiple sclerosis: case-control evidence of a relationship.

Authors:  S Warren; S Greenhill; K G Warren
Journal:  J Chronic Dis       Date:  1982

10.  Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer.

Authors:  S M Levy; R B Herberman; M Lippman; T D'Angelo; J Lee
Journal:  Behav Med       Date:  1991       Impact factor: 3.104

View more
  12 in total

Review 1.  Stress and multiple sclerosis.

Authors:  David C Mohr
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

2.  Coping strategies in relapsing-remitting multiple sclerosis non-depressed patients and their associations with disease activity.

Authors:  Gabriella Santangelo; Marida Della Corte; Maddalena Sparaco; Giuseppina Miele; Federica Garramone; Maria Cropano; Sabrina Esposito; Luigi Lavorgna; Antonio Gallo; Gioacchino Tedeschi; Simona Bonavita
Journal:  Acta Neurol Belg       Date:  2019-09-30       Impact factor: 2.396

Review 3.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

4.  Psychological stress is associated with relapse in type 1 autoimmune hepatitis.

Authors:  Savita Srivastava; James L Boyer
Journal:  Liver Int       Date:  2010-09-16       Impact factor: 5.828

5.  A randomized trial of stress management for the prevention of new brain lesions in MS.

Authors:  David C Mohr; Jesus Lovera; Ted Brown; Bruce Cohen; Thomas Neylan; Roland Henry; Juned Siddique; Ling Jin; David Daikh; Daniel Pelletier
Journal:  Neurology       Date:  2012-07-11       Impact factor: 9.910

6.  Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients.

Authors:  Stacey Hart; Irina Fonareva; Natalia Merluzzi; David C Mohr
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

7.  Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?

Authors:  M N Burns; E Nawacki; M J Kwasny; D Pelletier; D C Mohr
Journal:  Psychol Med       Date:  2013-05-17       Impact factor: 7.723

Review 8.  Coping with neuroimmunological diseases.

Authors:  Thomas Klauer; Wolfgang Schneider; Uwe K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

9.  Health-related quality of life outcomes at 1 and 5 years after a residential retreat promoting lifestyle modification for people with multiple sclerosis.

Authors:  Emily J Hadgkiss; George A Jelinek; Tracey J Weiland; Greg Rumbold; Claire A Mackinlay; Siegfried Gutbrod; Ian Gawler
Journal:  Neurol Sci       Date:  2012-02-25       Impact factor: 3.307

Review 10.  Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress.

Authors:  Laia Briones-Buixassa; Raimon Milà; Josep Mª Aragonès; Enric Bufill; Beatriz Olaya; Francesc Xavier Arrufat
Journal:  Health Psychol Open       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.